Last reviewed · How we verify
NCT05674552: EKERSE
Exogenous Ketone Esters for Refractory Status Epileptics
Phase 2, PHASE3 trial testing Exogenous ketone ester in Status Epilepticus in 50 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 10 January 2023 |
| Primary completion | 30 June 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Exogenous ketone ester — full drug profile →
Conditions studied
- Status Epilepticus — all drugs for Status Epilepticus →
Sponsor
Sohag University
Who can join
Adults 1 to 10, any sex, with Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the efficacy of add-on exogenous ketone esters for the treatment of children with refractory generalized convulsive status epilepticus
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05674552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exogenous ketone ester
Trials testing the same drug.
- NCT06954675 — Comparison of Microbiome Changes in Healthy Adults Following Ketone Ester Consumption · NA · recruiting
- NCT05670847 — Exogenous Ketone Esters for Drug Resistant Epilepsy · Phase 2, PHASE3 · recruiting
Other recruiting trials for Status Epilepticus
Currently open trials in the same condition.
- NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
- NCT06194747 — Improving Status Epilepticus Treatment Times · NA · recruiting
- NCT06017973 — The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus · NA · recruiting
- NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
- NCT05839418 — Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status · recruiting
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05674552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 27 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05674552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing